Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.705    0.455 (10.71%)
Bid:
4.70
Ask:
4.74
Spread: 0.04 (0.851%)
Market Cap: £225.82m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Directorate Change

8 Jun 2011 07:00

RNS Number : 0183I
Seeing Machines Limited
08 June 2011
 



8 June 2011

SEEING MACHINES (the "Company")

 

CEO TO DEPART AT END OF CONTRACT

Seeing Machines Limited (AIM:SEE), a leading developer of advanced vision based industrial systems, announces today that CEO and Director Dr Nick Cerneaz will leave the Company in July 2011.

Dr Cerneaz has been with the Company since 2005 and took over as CEO in September 2005 and led the Company at the time of its listing on AIM in December 2005. For the six years that he has been with the company he has commuted to the Canberra head office from his home in Sydney where he lives with his wife and young family. Dr Cerneaz and the Board of Seeing Machines have agreed his tenure as CEO will conclude at the end of this contract. Dr Cerneaz has also agreed to assist the Company in a consulting capacity throughout a handover period as required.

The Board is currently conducting a search for a replacement to lead the Company, as it seeks to move through the next phase of growth and commercialisation. Seeing Machines manufactures a range of world leading products from fatigue management tools through to 3D visualisation and medical technologies, and the Board remains committed to driving a strategy of growth through commercialisation of these technologies and products.

Dr Cerneaz commented: "I have very much enjoyed the efforts and contribution I have made at Seeing Machines and greatly valued the opportunity to work with such a dedicated, professional and energetic team. We have successfully moved the Company through an extensive period of development and laid the foundations for tremendous commercial success ahead, particularly with significant contracts established in our DSS and faceAPI businesses and strong pipelines ahead. I wish to take this opportunity to thank all my colleagues and the stakeholders in the business that have encouraged and supported our efforts and wish the company well in its forward endeavours."

Chairman Bill Mobbs commenting on Dr Cerneaz's departure said: "The Board is extremely grateful to Nick for his leadership of the Company throughout his tenure which was characterised by strong commitment, professionalism, drive and enthusiasm in taking the Company forward. We wish Nick well in his future endeavours and join with everyone at Seeing Machines in thanking Nick wholeheartedly for his efforts on behalf of the Company. "

Enquiries:

Seeing Machines Limited

Bill Mobbs, Chairman

+61 (0) 2 6103 4700

Daniel Stewart & Company plc

Oliver Rigby

+44 (0) 20 7776 6550

Walbrook PR Ltd

 

Paul McManus

 

Paul Cornelius

+44 (0) 20 7933 8780+44 (0) 7980 541 893, paul.mcmanus@walbrookpr.com

+44 (0) 7866 384 707, paul.cornelius@walbrookir.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGMGGVDNRGMZM
Date   Source Headline
9th Jan 20247:00 amRNSSeeing Machines unveils latest Guardian technology
3rd Jan 20247:00 amRNSSeeing Machines to showcase technology at CES 2024
20th Dec 20237:00 amRNSSeeing Machines announces US$30M European OEM win
13th Dec 20238:02 amRNSSeeing Machines welcomes U.S. NHTSA announcement
12th Dec 20237:00 amRNSSeeing Machines Wins Prestigious Road Safety Award
29th Nov 20237:57 amRNSResult of AGM
24th Nov 20237:00 amRNSAGM – reminder and correction of login details
8th Nov 20237:00 amRNS16th Automotive program awarded & Q1 FY2024 KPIs
6th Nov 202311:26 amRNSDirector/PDMR Shareholding
31st Oct 202311:50 amRNSDirector/PDMR Shareholding
31st Oct 20237:00 amRNSNotice of AGM
27th Oct 20237:19 amRNSDirector/PDMR Shareholding
27th Oct 20237:13 amRNSDirector/PDMR Shareholding
25th Oct 20237:55 amRNSDirector/PDMR Shareholding
25th Oct 20237:00 amRNSBoard Changes
20th Oct 20239:30 amRNSDirector/PDMR Shareholding
20th Oct 20239:21 amRNSDirector/PDMR Shareholding
19th Oct 20238:47 amRNSDirector/PDMR Shareholding
18th Oct 202310:06 amRNSDirector/PDMR Shareholding
17th Oct 20239:41 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSYear End Results – FY2023
16th Oct 20237:00 amRNSDevelopment of aviation fatigue detection solution
14th Sep 20237:00 amRNSNotice of Full Year Results 2023
7th Sep 20235:31 pmRNSDirector/PDMR Shareholding
22nd Aug 20237:00 amRNSFY2023 Trading Update & Q4 KPIs
18th Jul 20237:30 amRNSDirector/PDMR Shareholding
30th Jun 20237:00 amRNSDirector/PDMR Shareholding
30th Jun 20237:00 amRNSCEO Incentive Plan
28th Jun 20231:44 pmRNSDirector/PDMR Shareholding
28th Jun 20237:00 amRNSDirector/PDMR Shareholding
26th Jun 202311:38 amRNSDirector/PDMR Shareholding
23rd Jun 20238:55 amRNSDirector/PDMR Shareholding
20th Jun 20237:30 amRNSCollaboration with synthetic data specialist
19th Jun 20238:00 amRNSSeeing Machines to attend Stifel Tech Conference
25th May 20239:53 amRNSDirector/PDMR Shareholding
22nd May 20239:46 amRNSDirector/PDMR Shareholding
16th May 20237:00 amRNSExclusive Agreement Signed with Collins Aerospace
4th May 20237:00 amRNSKey Performance Indicators Q3 FY2023
17th Apr 20239:29 amRNSDirector/PDMR Shareholding
13th Apr 202312:36 pmRNSDirector/PDMR Shareholding
11th Apr 202311:15 amRNSPDMR Shareholding
6th Apr 20232:45 pmRNSDirector/PDMR Shareholding
5th Apr 20239:08 amRNSPDMR Shareholding
31st Mar 202312:26 pmRNSPDMR Shareholding
29th Mar 202311:55 amRNSDirector/PDMR Shareholding
28th Mar 202311:28 amRNSPDMR Shareholding
27th Mar 202310:12 amRNSDirector/PDMR Shareholding
27th Mar 202310:07 amRNSDirector/PDMR Shareholding
24th Mar 202311:56 amRNSPDMR Shareholding
24th Mar 20238:59 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.